News & Events
For Faculty & Staff
Bioprinting Technology Company Founded by Clarkson University Professor Listed on New York Stock Exchange
Prof. Gabor Forgacs, executive and scientific director of Clarkson University's Shipley Center for Innovation and Czanderna and Shirkey Professor in Physics, and the leadership of Organovo rang the opening bell at the New York Stock Exchange, Monday morning, to celebrate its NYSE listing.
Forgacs is the scientific founder of Organovo, a San Diego-based biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology.
Forgacs is a pioneer of bioprinting, a novel engineering technology to build tissues on demand. He is also the scientific founder of Modern Meadow, a biotech company focused on commercializing tissue engineering technologies for the ethical fabrication of animal products.
Forgacs started his first biophysics lab in 1994 at Clarkson, where he was on the physics faculty from 1986-2000, returning to Clarkson in 2009, after joining the faculty of the University of Missouri-Columbia as the George H. Vineyard Professor of Biological Physics, where he continues to do research.
Organ printing work was begun at University of Missouri–Columbia in 2004-2005, when a $5 million National Science Foundation Frontiers in Integrative Biological Research (FIBR) grant was awarded to a multi-institution team led by Forgacs. The first patent application for the NovoGen bioprinting platform, Self-Assembling Cell-Aggregates and Methods of Making the Same, was filed by Forgacs and others during the same time frame. In 2007, Organovo Inc. was incorporated with the intent to license the Forgacs patent suite and launch a 3D bioprinting company.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the technology has been featured in The Wall Street Journal, Time, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at http://www.organovo.com.
Clarkson University launches leaders into the global economy. One in five alumni already leads as a CEO, VP or equivalent senior executive of a company. Located just outside the Adirondack Park in Potsdam, N.Y., Clarkson is a nationally recognized research university for undergraduates with select graduate programs in signature areas of academic excellence directed toward the world's pressing issues. Through 50 rigorous programs of study in engineering, business, arts, sciences and health sciences, the entire learning-living community spans boundaries across disciplines, nations and cultures to build powers of observation, challenge the status quo, and connect discovery and engineering innovation with enterprise.
Photo caption: Prof. Gabor Forgacs (fifth from left), executive and scientific director of Clarkson University's Shipley Center for Innovation and Czanderna and Shirkey Professor in Physics, and the leadership of Organovo rang the opening bell at the New York Stock Exchange, Monday morning, to celebrate its NYSE listing.
[A photograph for media use is available at http://www.clarkson.edu/news/photos/forgacs-nyse.jpg .]